News | November 10, 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Strides is the first Indian company to get approval for the product.
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
To be marketed by Strides Pharma Inc. in the US market
Subscribe To Our Newsletter & Stay Updated
